Suppliers and packagers for generic pharmaceutical drug: DESMOPRESSIN ACETATE

DESMOPRESSIN ACETATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Nordic Pharma	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938	NDA	Ferring Pharmaceuticals Inc.	55566-2200-0	10 AMPULE in 1 CARTON (55566-2200-0) / 1 mL in 1 AMPULE	1984-05-01
Nordic Pharma	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938	NDA	Ferring Pharmaceuticals Inc.	55566-2300-0	1 VIAL, MULTI-DOSE in 1 CARTON (55566-2300-0) / 10 mL in 1 VIAL, MULTI-DOSE	1984-05-01
Nordic Pharma	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938	NDA	Nordic Pharma, Inc.	69918-899-01	1 mL in 1 AMPULE (69918-899-01)	2016-01-20
Nordic Pharma	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938	NDA	Nordic Pharma, Inc.	69918-899-10	10 AMPULE in 1 CARTON (69918-899-10) / 1 mL in 1 AMPULE	2016-01-20
Nordic Pharma	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938	NDA	Nordic Pharma, Inc.	69918-899-11	10 AMPULE in 1 CARTON (69918-899-11) / 1 mL in 1 AMPULE	2016-01-20

Desmopressin Acetate Supply Chain Analysis

Last updated: February 19, 2026

This report details the current landscape of desmopressin acetate suppliers, focusing on active pharmaceutical ingredient (API) manufacturers, finished drug product manufacturers, and key regulatory considerations. The analysis is critical for R&D and investment decisions concerning this synthetic analogue of vasopressin.

What is Desmopressin Acetate?

Desmopressin acetate is a synthetic peptide used clinically for its antidiuretic properties. It mimics the action of endogenous vasopressin but has a longer duration of action and reduced pressor activity. Its primary therapeutic indications include treating central diabetes insipidus, nocturnal enuresis in children, and certain bleeding disorders like mild hemophilia A and von Willebrand disease [1, 2]. The molecule's chemical structure is 1-deamino-1-monocarba-2-(O-ethyl)-D-arginine vasopressin acetate.

Who Manufactures Desmopressin Acetate API?

The production of desmopressin acetate API is concentrated among a limited number of specialized chemical manufacturers. These companies possess the expertise in peptide synthesis and purification required for this complex molecule.

Key API Suppliers:

• Bachem AG: A leading global manufacturer of peptides for the pharmaceutical and biotech industries. Bachem has a long-standing presence in peptide API production and offers desmopressin acetate. Their facilities are compliant with cGMP standards.
• Polypeptide Group: Another major player in custom peptide synthesis. Polypeptide has multiple manufacturing sites globally, equipped for large-scale peptide API production, including desmopressin acetate. They adhere to stringent quality control measures.
• Orpegen Pharma GmbH: Specializes in the development and manufacturing of peptide-based active pharmaceutical ingredients. Orpegen Pharma supplies desmopressin acetate and operates under GMP conditions.
• Other Regional Manufacturers: While the global supply is dominated by a few key players, smaller, regional manufacturers may also produce desmopressin acetate API, often serving local markets or specific contract manufacturing needs. Identifying these requires detailed market intelligence and regulatory database searches.

The synthesis of desmopressin acetate involves solid-phase peptide synthesis (SPPS) or liquid-phase peptide synthesis (LPPS), followed by specific modifications and purification steps. The process demands high purity to meet pharmacopoeial standards, such as those outlined in the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP).

What are the Finished Drug Product Manufacturers for Desmopressin Acetate?

The finished desmopressin acetate drug products are formulated into various dosage forms, including oral tablets, nasal sprays, and parenteral injections. This diversification requires different manufacturing capabilities and regulatory approvals.

Major Finished Drug Product Manufacturers:

• Teva Pharmaceuticals Industries Ltd.: A significant global pharmaceutical company that manufactures generic versions of desmopressin acetate products. Teva holds marketing authorizations in various regions.
• Ipsen S.A.: The originator company of desmopressin acetate (marketed as DDAVP®). Ipsen continues to manufacture and market branded desmopressin acetate products.
• Ferring Pharmaceuticals: Known for its work with peptide-based therapeutics, Ferring Pharmaceuticals is a key manufacturer and marketer of desmopressin acetate in different formulations.
• AURO Pharmaceutical (a subsidiary of Aurobindo Pharma): Aurobindo Pharma, through its subsidiaries like AURO Pharmaceutical, is involved in the production and supply of generic desmopressin acetate.
• Par Pharmaceutical (an Endo International plc company): Par Pharmaceutical manufactures and markets generic desmopressin acetate products, contributing to market access and affordability.
• Bausch Health Companies Inc.: Formerly Valeant Pharmaceuticals, Bausch Health also offers desmopressin acetate products within its portfolio.

The manufacturing of finished drug products must comply with Good Manufacturing Practices (GMP) specific to the formulation type. Nasal sprays, for instance, require specialized sterile manufacturing and device integration. Oral tablets involve standard solid dosage form manufacturing processes. Parenteral solutions demand aseptic processing and stringent control over particulate matter and sterility.

What are the Regulatory Considerations for Desmopressin Acetate?

Regulatory compliance is paramount for all parties involved in the desmopressin acetate supply chain, from API synthesis to finished drug product distribution. Key regulatory bodies and their requirements are critical for market entry and sustained operations.

Key Regulatory Bodies and Frameworks:

• U.S. Food and Drug Administration (FDA): The FDA oversees drug approval, manufacturing, and post-market surveillance in the United States. Manufacturers must file New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for finished products and Drug Master Files (DMFs) for APIs. Facilities are subject to regular FDA inspections.
• European Medicines Agency (EMA): The EMA is responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union. Marketing Authorization Applications (MAAs) are submitted for finished products. Active Substance Master Files (ASMFs) are used for API information.
• Pharmaceuticals and Medical Devices Agency (PMDA) in Japan: The PMDA regulates pharmaceuticals in Japan, requiring similar dossier submissions and facility compliance.
• Other National Regulatory Authorities: Health Canada, the Therapeutic Goods Administration (TGA) in Australia, and numerous other national agencies have their own specific requirements for drug approval and manufacturing site inspections.

Key Regulatory Aspects:

• Good Manufacturing Practices (GMP): All manufacturing sites, whether for API or finished drug products, must adhere to cGMP guidelines. This includes robust quality management systems, process validation, impurity profiling, and stability testing [3].
• Drug Master Files (DMFs)/Active Substance Master Files (ASMFs): API manufacturers submit comprehensive information about their manufacturing process, controls, and specifications in DMFs or ASMFs. These are referenced by finished product manufacturers in their regulatory submissions, allowing for protection of proprietary information while demonstrating API quality [4].
• Pharmacopoeial Standards: Desmopressin acetate must meet the specifications outlined in relevant pharmacopoeias, such as the USP and EP. These monographs detail tests for identity, purity, assay, and related substances, ensuring product consistency and safety [5].
• Impurity Control: Strict controls on process-related impurities, degradation products, and enantiomeric purity are essential. The presence of specific impurities can impact drug safety and efficacy and is closely scrutinized by regulatory agencies.
• Stability Studies: Comprehensive stability studies under various temperature and humidity conditions are required to establish shelf life and storage conditions for both the API and the finished drug product [3].

What are the Supply Chain Risks and Mitigation Strategies?

The desmopressin acetate supply chain, like many in the pharmaceutical industry, faces inherent risks that can impact availability and cost.

Identified Risks:

• Limited API Supplier Base: The specialized nature of peptide synthesis means a relatively small number of companies can produce desmopressin acetate API at scale. This concentration can lead to supply disruptions if a key supplier experiences manufacturing issues, regulatory challenges, or goes out of business.
• Regulatory Hurdles: Changes in regulatory requirements, unexpected inspection failures, or delays in approval for new manufacturing sites or processes can disrupt supply.
• Geopolitical and Economic Factors: Global events, trade disputes, or economic instability can affect raw material sourcing, logistics, and manufacturing costs.
• Quality Control Issues: Any lapse in quality control at either the API or finished product stage can lead to batch recalls, regulatory actions, and significant supply interruptions.
• Patent Expirations and Generic Competition: While desmopressin acetate has been on the market for a considerable time, patent landscapes for specific formulations or manufacturing processes can still influence market dynamics and competition.

Mitigation Strategies:

• Dual Sourcing for API: Establishing relationships with at least two qualified desmopressin acetate API suppliers can significantly mitigate the risk of single-source dependence. This requires rigorous qualification of each supplier and may involve dual manufacturing agreements.
• Robust Quality Agreements: Implementing comprehensive quality agreements with all suppliers, detailing specifications, testing, change control, and notification procedures, is crucial.
• Proactive Regulatory Engagement: Maintaining open communication with regulatory authorities and staying abreast of evolving guidelines can help prevent unexpected compliance issues. Conducting regular internal audits and gap analyses against current GMP standards is advisable.
• Supply Chain Mapping and Transparency: Thoroughly mapping the entire supply chain, including critical raw material suppliers, can identify potential vulnerabilities. Building transparency with suppliers regarding their own supply chains is also beneficial.
• Inventory Management: Strategic inventory management, including holding safety stocks of critical raw materials and finished goods, can buffer against short-term supply disruptions. However, this must be balanced against shelf-life limitations and storage costs.
• Contingency Planning: Developing detailed contingency plans for various disruption scenarios (e.g., natural disasters, supplier failure, regulatory actions) allows for a more rapid and effective response.

What is the Market Outlook for Desmopressin Acetate?

The market for desmopressin acetate is influenced by its established therapeutic uses and the ongoing demand for treatments for diabetes insipidus and nocturnal enuresis. The increasing prevalence of these conditions, coupled with an aging population, supports sustained demand.

• Generic Market Growth: The availability of generic desmopressin acetate products has increased market accessibility and driven down costs, contributing to broader patient access. Generic competition remains a significant factor influencing pricing and market share.
• New Formulations and Delivery Systems: While desmopressin acetate is a mature drug, research into novel delivery systems or combination therapies could emerge, potentially creating new market opportunities or extending product lifecycles. However, significant innovation in this area is less common for established peptide drugs.
• Geographic Market Expansion: Increased healthcare access in emerging economies could lead to greater demand for desmopressin acetate, provided regulatory pathways are navigated effectively.
• Competition from Alternative Therapies: For some indications, alternative treatments exist. For example, in nocturnal enuresis, behavioral therapies and other pharmacological agents compete with desmopressin. In diabetes insipidus, desmopressin remains a cornerstone therapy for central forms.
• Pricing Pressures: Intense competition within the generic market, coupled with payer pressure to control healthcare costs, exerts significant pricing pressure on desmopressin acetate products.

The long-term outlook for desmopressin acetate is one of continued, stable demand driven by its efficacy in well-defined indications. Market dynamics will largely be shaped by generic competition, regulatory environments, and global healthcare spending trends.

Key Takeaways

• Desmopressin acetate API manufacturing is concentrated among a few specialized peptide synthesis companies, including Bachem AG, Polypeptide Group, and Orpegen Pharma GmbH.
• Finished desmopressin acetate drug products are manufactured by a diverse group of pharmaceutical companies, including Teva Pharmaceuticals, Ipsen S.A., and Ferring Pharmaceuticals, across various dosage forms.
• Strict adherence to cGMP, robust quality agreements, and comprehensive regulatory submissions (DMFs/ASMFs, ANDAs/MAAs) are critical for market access and supply chain integrity.
• Supply chain risks include a limited API supplier base and regulatory complexities, necessitating strategies such as dual sourcing and proactive regulatory engagement.
• The market is characterized by established demand for its therapeutic indications and ongoing generic competition, leading to pricing pressures and a focus on cost-effective manufacturing.

Frequently Asked Questions

1. How does the FDA's Drug Master File (DMF) system impact desmopressin acetate API sourcing?

The FDA's DMF system allows API manufacturers to provide confidential detailed information about their manufacturing process, facilities, and quality controls directly to the FDA. Finished drug product manufacturers then reference these DMFs in their own drug applications (NDAs/ANDAs). This system facilitates the evaluation of API quality without requiring the API manufacturer to disclose proprietary information to the drug product manufacturer, streamlining the sourcing and approval process for desmopressin acetate API by demonstrating its compliance with FDA standards.

2. Are there specific challenges in manufacturing desmopressin acetate nasal spray formulations compared to oral tablets?

Yes, manufacturing desmopressin acetate nasal spray formulations presents unique challenges. These include maintaining sterility throughout the filling and packaging process, ensuring precise and consistent droplet size and spray pattern for accurate dosing, and integrating the drug product with the specialized spray device. Oral tablets, while requiring GMP compliance, generally involve more conventional solid dosage form manufacturing techniques and less stringent sterility requirements.

3. What is the typical lifecycle stage for desmopressin acetate in the pharmaceutical market?

Desmopressin acetate is considered a mature pharmaceutical product. It is off-patent in its originator form and has a well-established generic market. While significant new therapeutic indications are unlikely, innovation may occur in novel delivery systems or formulations to improve patient compliance or efficacy, potentially extending its commercial lifecycle.

4. How do pharmacopoeial monographs for desmopressin acetate ensure product quality and consistency?

Pharmacopoeial monographs, such as those in the USP and EP, establish legally recognized standards for drug substances and products. For desmopressin acetate, the monograph specifies tests for identity, purity (including limits for specified and unspecified impurities), assay (content of the active ingredient), water content, and other critical quality attributes. Compliance with these monographs ensures that each batch of desmopressin acetate API and finished product meets a defined level of quality and is suitable for its intended therapeutic use.

5. What are the implications of single-source API manufacturing for desmopressin acetate on drug product availability?

A single-source API manufacturer for desmopressin acetate creates a significant vulnerability. Any interruption at that single manufacturing site, whether due to a quality issue, regulatory action, production problem, or business cessation, can lead to a critical shortage of the API. This shortage directly impacts the ability of finished drug product manufacturers to produce and supply desmopressin acetate to patients, potentially leading to widespread product unavailability and treatment disruptions.

Citations

[1] Glick, M. B., & Loria, A. (2000). Desmopressin. The Medical Clinics of North America, 84(6), 1185–1200. https://doi.org/10.1016/s0025-7125(00)00059-0

[2] American Society of Health-System Pharmacists. (n.d.). Desmopressin Acetate. In American Hospital Formulary Service® Drug Information®. Retrieved from ASHP Plus.

[3] U.S. Food and Drug Administration. (2023, June 20). Guidance for Industry: ANDAs: Pharmaceutical Quality/CMC. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidance-industry

[4] European Medicines Agency. (2016, March 25). Guideline on the management of Drug Master Files (ASMF). Retrieved from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-management-drug-master-files-asmf-revision-2_en.pdf

[5] United States Pharmacopeial Convention. (n.d.). Pharmacopeial Forum. Retrieved from https://www.uspnf.com/